Health CarePharmaceuticals & Biotechnology
  • Price (GBX)1,404.00
  • Today's Change9.00 / 0.65%
  • Shares traded125.34k
  • 1 Year change-45.35%
  • Beta1.3504
Data delayed at least 20 minutes, as of Jul 25 2017 13:19 BST.
More ▼

Key statistics

As of last trade Hikma Pharmaceuticals PLC (HIK:LSE) traded at 1,404.00, 4.82% above its 52-week low of 1,339.50, set on Jul 12, 2017.
52-week range
1,339.50Jul 12 20172,703.00Aug 02 2016
Markit short selling activity
Previous close1,395.00
Average volume642.65k
Shares outstanding240.65m
Free float131.39m
P/E (TTM)27.52
Market cap3.35bn GBP
EPS (TTM)0.5056
Annual div (ADY)26.40
Annual div yield (ADY)1.89%
Div ex-dateApr 06 2017
Div pay-dateMay 25 2017
Data delayed at least 20 minutes, as of Jul 25 2017 13:19 BST.
More ▼

Investors Chronicle View

The last IC recommendation on Hikma Pharmaceuticals PLC shares was Sell at 2,126.00 on 15 Mar 2017Read the full article

Board of Directors


Said Darwazah, Chairman and Chief Executive


Mazen Darwazah, Executive Vice Chairman, Chief Executive of MENA and Emerging Markets


Ali Al-Husry, Non-Executive Director


Dr. Jochen Gann, Non-Executive Director


Robert Pickering, Chair of the Nomination Committee


Dr. Pamela Kirby, Chair Remuneration Committee


Michael Ashton, Independent Non-Executive Director


Dr. Ronald Goode, Chair Compliance, Responsibility and Ethics Committee


Patrick Butler, Chair Audit Committee


John Castellani, Independent Non-Executive Director


Nina Henderson, Independent Non-Executive Director

Investor Relations Contact

Susan Ringdal
Investor Relations Director
Email: susan.ringdal@hikma.uk.com
Tel: +44 (0) 20 7399 2760
Fax: +44 (0) 20 7399 2761

Hikma Pharmaceuticals PLC
13 Hanover Square
London W1S 1HW

© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.